Two Cancer Drug Advances Show Promise in Early Research
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
T-Cell Exclusion
BiomarkerRelated News
Existing Drug May Overcome Immunotherapy Resistance in Rare Liver Cancer
Study finds FDA-approved drug AMD3100 can mobilize immune T cells to attack fibrolamellar carcinoma, a rare liver cancer affecting children and young adults that has resisted immunotherapy treatment.
FDA-Approved Drug AMD3100 May Enable Immunotherapy for Rare Liver Cancer
Researchers find that AMD3100, an existing FDA-approved drug, can reverse T-cell exclusion in fibrolamellar carcinoma, potentially allowing immunotherapy to fight the rare and fatal liver cancer that primarily affects children and young adults.